Poland· PL-100028194
Sympramol
A opipramol product containing opipramoli dihydrochloridum, registered in Poland by Farmak International Sp. z o.o.. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Opipramol is registered in 5 of 19 countries.
Countries holding a registration under ATC N06AA05 (opipramol), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Opipramol · ATC N06AA05
5 / 19 countries
- Finlandprice
- Germany
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Opipramoli dihydrochloridum
- Manufacturer
- Farmak International Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- N06AA05
- ATC class
- Opipramol
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909990043132
- gtin05909990634620
- gtin05909990634637
- gtin05909990634644
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
36 interactions on record for opipramol.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Opipramol · interactions on record
36 records
36 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Opipramol in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- GermanyInsidonLaboratoires Juvise Pharmaceuticals
- SwitzerlandInsidon, DragéesMedius AG
- NorwayInsidonUkjent (2)
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Austria · Insidon
- Germany · Insidon, Ophel
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f144d050-e8be-4b9c-8c28-1aed3683baaa GET /v1/drugs/f144d050-e8be-4b9c-8c28-1aed3683baaa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki drażowane",
"source": "urpl",
"strength": "50 mg",
"packaging": "05909990043132 ¦ Rp ¦ 27759\n20 tabl.\n05909990634620 ¦ Rp ¦ 42173\n40 tabl.\n05909990634637 ¦ Rp ¦ 42174\n60 tabl.\n05909990634644 ¦ Rp ¦ 42175\n90 tabl.",
"substance": "Opipramoli dihydrochloridum 50 mg",
"common_name": "Opipramoli dihydrochloridum",
"pl_product_id": "100028194",
"pozwolenie_nr": "12777",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about opipramol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.